查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370911

隐球菌病治疗市场，- 2018-2028 年全球产业规模、份额、趋势、机会和预测，按治疗、按配销通路、按地区、按竞争细分。

Cryptococcosis Therapeutics Market, - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Treatment, By Distribution Channel, By Region, By Competition.
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022年全球隐球菌病治疗市值为46.7亿美元，预计到2028年将呈现稳定成长，复合年增长率为4.34%，预计2028年将达到60.4亿美元。隐球菌病主要表现为肺部和中枢神经系统感染，表现出从轻微的呼吸道问题到严重的神经系统併发症的症状。致病真菌常见于环境中，特别是在被鸟粪污染的土壤中。吸入后，真菌孢子会导致感染，特别是对于易受此类疾病影响的个体。在爱滋病毒/爱滋病流行、器官移植和其他免疫抑制状态等因素的推动下，免疫功能低下患者的盛行率不断增加，大大加剧了隐球菌病负担的不断上升。随着研究工作不断产生改进的治疗方案，隐球菌病治疗市场有望成长。製药公司、学术机构和公共卫生组织的合作对于推动这些创新至关重要。随着新型抗真菌药物、联合疗法和製剂的出现，受隐球菌病影响的个体的前景预计将得到改善，从而提高他们的生活品质和生存率。

主要市场驱动因素

免疫功能低下疾病盛行率的上升推动了隐球菌病治疗市场：近年来，患有免疫功能低下疾病的人数显着增加。全球爱滋病毒/爱滋病流行仍是隐球菌病流行的重要因素。儘管爱滋病毒治疗和预防方面取得了长足进步，但许多人仍然无法获得足够的医疗保健，使他们容易受到隐球菌病等机会性感染。器官移植和癌症治疗的日益普及为患者带来了新的希望，同时削弱了他们的免疫系统。随着医学进步延长了器官移植受者和癌症倖存者的寿命，免疫系统受损的人口正在增加。免疫功能低下个体中隐球菌病患病率的上升趋势促进了隐球菌病疗法的发展。因此，该市场见证了研发工作的激增。製药公司正在努力开发更有效、毒性更低且可供更广泛患者群体使用的药物。隐球菌病的着名治疗选择包括抗真菌药物，如两性霉素 B、氟康唑和氟胞嘧啶。然而，这些药物在功效和潜在副作用方面可能存在局限性，从而推动了对创新治疗解决方案的需求。研究人员正在积极探索新型抗真菌化合物、联合疗法和免疫调节剂，以提高治疗效果并减轻免疫功能低下患者的隐球菌病负担。

市场概况
预测期 2024-2028
2022 年市场规模 46.7亿美元
2028 年市场规模 60.4亿美元
2023-2028 年复合年增长率 4.34%
成长最快的细分市场 氟胞嘧啶
最大的市场 北美洲

公众健康意识的提高推动了隐球菌病治疗市场：公众健康意识的高涨相应地产生了对有效的隐球菌病治疗的需求。这种需求反过来又刺激了隐球菌病治疗市场的成长。製药公司和研究人员已经认识到需要创新疗法来对抗这种真菌感染并提高患者的生活品质。随着市场努力提供更有效的治疗方法，研发投资大幅增加。这激发了对新候选药物、治疗方法和临床试验的探索。解决全球隐球菌病负担的迫切性推动了新型抗真菌药物、联合疗法和免疫调节疗法的开发。公共卫生意识引发了学术界、製药公司和研究机构之间的合作。认识到隐球菌病不仅是一个医学挑战，而且是一个社会问题，这促使利益相关者合作开发创新解决方案。研究伙伴关係、政府倡议和非营利组织正在汇集资源来推动隐球菌病治疗领域的发展。此外，公共卫生意识的提高吸引了创投家和资助组织的投资。市场大幅扩张的潜力，加上解决危及生命的感染的人道主义方面，为研究和临床试验提供了财政支持。

真菌感染的复杂性提出了关键挑战：像隐球菌病这样的真菌感染非常复杂，需要对真菌生物学、宿主相互作用和抗药性机制有深刻的了解，才能开发有效的治疗方法。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球隐球菌病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依治疗（两性霉素 B、氟胞嘧啶、氟康唑、其他）
    • 按配销通路（医院、零售药局、专科诊所、其他）
    • 按地区
    • 按公司划分（前 5 名市场参与者的股份）
  • 市场地图
    • 按治疗
    • 按配销通路
    • 按地区

第 6 章：北美隐球菌病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按治疗
    • 按配销通路
    • 按国家/地区

第 7 章：欧洲隐球菌病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按治疗
    • 按配销通路
    • 按国家/地区

第 8 章：亚太地区隐球菌病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按治疗
    • 按配销通路
    • 按国家/地区

第 9 章：南美隐球菌病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按配销通路
    • 按国家/地区

第 10 章：中东和非洲隐球菌病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按配销通路
    • 按国家/地区

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 治疗启动

第13章：竞争格局

  • 安斯泰来製药公司
  • 百时美施贵宝公司
  • 格兰马克製药公司
  • 杨森生物技术公司（Johnson & Johnson Services, Inc.）
  • 诺华公司
  • 辉瑞公司
  • 旭化成製药
  • Sigmapharm 实验室有限责任公司

第 14 章：策略建议

第 15 章：关于我们与免责声明

简介目录
Product Code: 15909

The Global Cryptococcosis Therapeutics Market, valued at USD 4.67 Billion in 2022, is expected to exhibit steady growth with a CAGR of 4.34% through 2028 and expected to reach USD 6.04 Billion in 2028. Cryptococcosis predominantly manifests as a pulmonary and central nervous system infection, exhibiting symptoms ranging from mild respiratory issues to severe neurological complications. The causative fungus is commonly found in the environment, particularly in soil contaminated by bird droppings. When inhaled, the fungal spores can lead to infections, especially in individuals susceptible to such conditions. The increasing prevalence of immunocompromised patients, driven by factors like the HIV/AIDS epidemic, organ transplants, and other immunosuppressive states, has significantly contributed to the escalating burden of cryptococcosis. As research endeavors continue to yield improved treatment options, the cryptococcosis therapeutics market is poised for growth. Collaborative efforts involving pharmaceutical companies, academic institutions, and public health organizations will be pivotal in advancing these innovations. With the emergence of new antifungal agents, combination therapies, and formulations, the outlook for individuals affected by cryptococcosis is expected to improve, enhancing their quality of life and survival rates.

Primary Market Drivers

Rising Prevalence of Immunocompromised Conditions Drives the Cryptococcosis Therapeutics Market: In recent years, there has been a noticeable surge in the number of individuals grappling with immunocompromised conditions. The global HIV/AIDS epidemic remains a significant contributor to the prevalence of cryptococcosis. Despite strides in HIV treatment and prevention, many individuals still lack access to adequate healthcare, rendering them susceptible to opportunistic infections such as cryptococcosis. The increasing prevalence of organ transplantation and cancer treatments offers newfound hope to patients while simultaneously weakening their immune systems. As medical advancements extend the lifespans of organ transplant recipients and cancer survivors, the population living with compromised immune systems is on the rise. This upward trajectory in cryptococcosis prevalence among immunocompromised individuals has catalyzed the development of cryptococcosis therapeutics. Consequently, this market has witnessed a surge in research and development endeavors. Pharmaceutical companies are striving to create drugs that are more effective, less toxic, and accessible to a broader patient base. Notable treatment options for cryptococcosis include antifungal drugs like amphotericin B, fluconazole, and flucytosine. However, these medications may have limitations in terms of efficacy and potential side effects, driving the need for innovative therapeutic solutions. Researchers are actively exploring novel antifungal compounds, combination therapies, and immune-modulating agents to enhance treatment outcomes and alleviate the burden of cryptococcosis among immunocompromised patients.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 4.67 Billion
Market Size 2028USD 6.04 Billion
CAGR 2023-20284.34%
Fastest Growing SegmentFlucytosine
Largest MarketNorth America

Rising Public Health Awareness Propels the Cryptococcosis Therapeutics Market: The upsurge in public health awareness has correspondingly generated demand for effective cryptococcosis treatments. This demand, in turn, has stimulated growth within the cryptococcosis therapeutics market. Pharmaceutical companies and researchers have recognized the necessity for innovative therapies to combat this fungal infection and enhance patients' quality of life. Investments in research and development have surged substantially as the market endeavors to offer more effective treatments. This has instigated the exploration of new drug candidates, therapeutic approaches, and clinical trials. The development of novel antifungal agents, combination therapies, and immunomodulatory treatments has been driven by the growing urgency to address the global cryptococcosis burden. Public health awareness has sparked collaboration between academia, pharmaceutical firms, and research institutions. The recognition that cryptococcosis is not just a medical challenge but a societal issue has motivated stakeholders to collaborate on innovative solutions. Research partnerships, governmental initiatives, and nonprofit organizations are pooling resources to advance the field of cryptococcosis therapeutics. Furthermore, heightened public health awareness has garnered investment from venture capitalists and funding organizations. The potential for substantial market expansion, coupled with the humanitarian aspect of addressing a life-threatening infection, has resulted in financial support for research and clinical trials.

Complexity of Fungal Infections Presents Key Challenges: Fungal infections like cryptococcosis are intricate, requiring a profound understanding of fungal biology, host interactions, and resistance mechanisms to develop effective treatments.

Clinical Trial Design Poses Challenges: Conducting clinical trials for antifungal drugs is challenging due to the need for specialized patient populations and appropriate study endpoints.

Affordability and Access Remain Significant Challenges: Ensuring that innovative treatments are affordable and accessible, particularly in resource-limited settings, remains a crucial challenge.

Technological Advancements Drive Market Trends: Advancements in diagnostic techniques have revolutionized cryptococcosis detection, leading to earlier and more accurate diagnoses. Molecular diagnostic methods like polymerase chain reaction (PCR) have enabled the detection of Cryptococcus DNA in patient samples. PCR amplifies specific DNA sequences, enabling the detection of even small amounts of fungal DNA. This technique's sensitivity allows for the identification of the fungus in blood or cerebrospinal fluid, facilitating swift diagnosis and treatment initiation. Antigen detection assays have proven valuable for diagnosing cryptococcosis. These assays identify specific fungal antigens, such as Cryptococcus' capsular polysaccharide, in patient samples. Antigen detection tests are highly sensitive and can be conducted on blood or cerebrospinal fluid, aiding in early infection detection. Advanced imaging techniques like computed tomography (CT) and magnetic resonance imaging (MRI) have enhanced the visualization of fungal infections within the body, especially when they have spread to the central nervous system.

Segmental and Regional Insights: The Flucytosine segment dominated the Cryptococcosis Therapeutics market in 2022 and is predicted to continue its expansion. Hospitals, particularly in North America, play a pivotal role in prompt cryptococcosis diagnosis and treatment, owing to their advanced healthcare infrastructure.

Key Market Players

  • Astellas Pharma Inc
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals
  • Janssen Biotech Inc.( Johnson & Johnson Services, Inc.)
  • Novartis AG
  • Pfizer Inc
  • Asahi Kasei Pharma
  • Sigmapharm Laboratories LLC

Report Scope:

  • In this report, the Global Cryptococcosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Cryptococcosis Therapeutics Market, By Treatment:

  • Amphotericin B
  • Flucytosine
  • Fluconazole
  • Other

Cryptococcosis Therapeutics Market, By Distribution Channel:

  • Hospitals
  • Retail Pharmacies
  • Specialty Clinics
  • Others

Cryptococcosis Therapeutics Market, By Region:

  • North America
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • South America

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Cryptococcosis Therapeutics Market.

Available Customizations:

  • Global Cryptococcosis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cryptococcosis Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Amphotericin B, Flucytosine, Fluconazole, Others)
    • 5.2.2. By Distribution Channel (Hospitals, Retail Pharmacies, Specialty Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (Shares of Top 5 Market Players)
  • 5.3. Market Map
    • 5.3.1. By Treatment
    • 5.3.2. By Distribution Channel
    • 5.3.3. By Region

6. North America Cryptococcosis Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
      • 6.2.3.1. United States Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.1.1. Market Size & Forecast
        • 6.2.3.1.1.1. By Value
        • 6.2.3.1.2. Market Share & Forecast
        • 6.2.3.1.2.1. By Treatment
        • 6.2.3.1.2.2. By Distribution Channel
      • 6.2.3.2. Canada Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.2.1. Market Size & Forecast
        • 6.2.3.2.1.1. By Value
        • 6.2.3.2.2. Market Share & Forecast
        • 6.2.3.2.2.1. By Treatment
        • 6.2.3.2.2.2. By Distribution Channel
      • 6.2.3.3. Mexico Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.3.1. Market Size & Forecast
        • 6.2.3.3.1.1. By Value
        • 6.2.3.3.2. Market Share & Forecast
        • 6.2.3.3.2.1. By Test
        • 6.2.3.3.2.2. By Distribution Channel

7. Europe Cryptococcosis Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2.
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
      • 7.2.4.1. France Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
        • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Treatment
        • 7.2.4.1.2.2. By Distribution Channel
      • 7.2.4.2. Germany Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
        • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Treatment
        • 7.2.4.2.2.2. By Distribution Channel
      • 7.2.4.3. United Kingdom Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
        • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Treatment
        • 7.2.4.3.2.2. By Distribution Channel
      • 7.2.4.4. Italy Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
        • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Treatment
        • 7.2.4.4.2.2. By Distribution Channel
      • 7.2.4.5. Spain Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
        • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Treatment
        • 7.2.4.5.2.2. By Distribution Channel

8. Asia Pacific Cryptococcosis Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
      • 8.2.3.1. China Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.1.1. Market Size & Forecast
        • 8.2.3.1.1.1. By Value
        • 8.2.3.1.2. Market Share & Forecast
        • 8.2.3.1.2.1. By Treatment
        • 8.2.3.1.2.2. By Distribution Channel
      • 8.2.3.2. India Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.2.1. Market Size & Forecast
        • 8.2.3.2.1.1. By Value
        • 8.2.3.2.2. Market Share & Forecast
        • 8.2.3.2.2.1. By Treatment
        • 8.2.3.2.2.2. By Distribution Channel
      • 8.2.3.3. South Korea Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.3.1. Market Size & Forecast
        • 8.2.3.3.1.1. By Value
        • 8.2.3.3.2. Market Share & Forecast
        • 8.2.3.3.2.1. By Treatment
        • 8.2.3.3.2.2. By Distribution Channel
      • 8.2.3.4. Japan Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.4.1. Market Size & Forecast
        • 8.2.3.4.1.1. By Value
        • 8.2.3.4.2. Market Share & Forecast
        • 8.2.3.4.2.1. By Treatment
        • 8.2.3.4.2.2. By Distribution Channel
      • 8.2.3.5. Australia Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.5.1. Market Size & Forecast
        • 8.2.3.5.1.1. By Value
        • 8.2.3.5.2. Market Share & Forecast
        • 8.2.3.5.2.1. By Treatment
        • 8.2.3.5.2.2. By Distribution Channel

9. South America Cryptococcosis Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2.
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. Brazil Cryptococcosis Therapeutics Market Outlook
        • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
        • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Treatment
        • 9.2.4.1.2.2. By Distribution Channel
      • 9.2.4.2. Argentina Cryptococcosis Therapeutics Market Outlook
        • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
        • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Treatment
        • 9.2.4.2.2.2. By Distribution Channel
      • 9.2.4.3. Colombia Cryptococcosis Therapeutics Market Outlook
        • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
        • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Treatment
        • 9.2.4.3.2.2. By Distribution Channel

10. Middle East & Africa Cryptococcosis Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
      • 10.2.3.1. South Africa Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.1.1. Market Size & Forecast
        • 10.2.3.1.1.1. By Value
        • 10.2.3.1.2. Market Share & Forecast
        • 10.2.3.1.2.1. By Treatment
        • 10.2.3.1.2.2. By Distribution Channel
      • 10.2.3.2. Saudi Arabia Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.2.1. Market Size & Forecast
        • 10.2.3.2.1.1. By Value
        • 10.2.3.2.2. Market Share & Forecast
        • 10.2.3.2.2.1. By Treatment
        • 10.2.3.2.2.2. By Distribution Channel
      • 10.2.3.3. UAE Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.3.1. Market Size & Forecast
        • 10.2.3.3.1.1. By Value
        • 10.2.3.3.2. Market Share & Forecast
        • 10.2.3.3.2.1. By Treatment
        • 10.2.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Treatment Launches

13. Competitive Landscape

  • 13.1. Astellas Pharma Inc
  • 13.2. Bristol-Myers Squibb Company
  • 13.3. Glenmark Pharmaceuticals
  • 13.4. Janssen Biotech Inc.( Johnson & Johnson Services, Inc.)
  • 13.5. Novartis AG
  • 13.6. Pfizer Inc
  • 13.7. Asahi Kasei Pharma
  • 13.8. Sigmapharm Laboratories LLC

14. Strategic Recommendations

15. About us & Disclaimer